$ARVN News

Arvinas (ARVN) Q2 2026 Earnings Call Transcript

Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14

Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $11

Wedbush Maintains Neutral on Arvinas, Raises Price Target to $12

Arvinas Q2 Earnings Call Highlights

BTIG Reiterates Buy on Arvinas, Maintains $18 Price Target

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Transcript: Arvinas Q2 2026 Earnings Conference Call

Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M Estimate

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Stephens & Co. Reiterates Overweight on Arvinas, Maintains $18 Price Target

Arvinas Announces Re-Prioritization Of Portfolio Following Strategic Review; Plans To Complete Phase 1 Monotherapy Dose Escalation Trial And Share Data In 2026; Plans To Seek Out-Licensing Agreement For Additional Clinical Trials Of ARV-806; Expects Cash Position As Of March 31, 2026 To Fund Operations Into Second Half Of 2028

Full Transcript: Arvinas Q1 2026 Earnings Call

Arvinas Employees Give Back During Company-wide Impact Day

Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts